Compared with classical oral-hypoglycemic drugs, biguanides, thiazolidinediones, sulfonylureas, and alpha glucosidase inhibitors, patients receiving DPP-4i treatment have a lower incidence of hypoglycemic events and gain less weight
Weekly drugs, such as injectable semaglutide or dulaglutide, can linger in the system for days
What makes semaglutide particularly interesting for MS patients is preclinical research indicating it may directly protect nerve cells and promote repair, alongside preliminary clinical evidence that MS patients on GLP-1 medications experience less disease progression
But the category is moving much faster than that
Interleukin-12 exacerbates Sjgrens syndrome through induction of myeloid-derived suppressor cells
Post-Market Surveillance & Feedback Ongoing monitoring of the drugs safety and effectiveness continues after market launch